RxDoctor Payments Data

James Ladd, MD

Family Medicine · Asheville, NCNPI 1790771244

Payments from drug & device makers

$10,004in general payments, 2019–2025

Across 647 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$815
  • AstraZeneca$714
  • GSK$708
  • Pfizer$655
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,004 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$231,976
Medicare patients
271
Services billed
5,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$141,462
JardianceEmpagliflozin114$95,828
XareltoRivaroxaban67$70,736
MounjaroTirzepatide34$53,401
Synjardy XrEmpagliflozin/Metformin Hcl42$45,282
FarxigaDapagliflozin Propanediol39$35,386
ProliaDenosumab20$34,976
RybelsusSemaglutide20$25,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$20,862
MyrbetriqMirabegron34$20,741
Repatha SureclickEvolocumab24$20,533
GlyxambiEmpagliflozin/Linagliptin24$19,303
GemtesaVibegron22$12,271
VascepaIcosapent Ethyl11$11,851
TradjentaLinagliptin16$10,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta$312$171,113196 claims
PfizerEliquis$655$141,462123 claims
Johnson & JohnsonXarelto$464$70,73667 claims
Lilly USA, LLCMounjaro$1,022$53,40134 claims
AstraZenecaFarxiga, Breztri Aerosphere$714$45,15253 claims
AmgenProlia$1,061$34,97620 claims
GSKTrelegy Ellipta, Anoro Ellipta$708$30,28543 claims
Novo NordiskRybelsus$815$25,48720 claims
Astellas Pharma US IncMyrbetriq$418$20,74134 claims
Sumitomo Pharma America, Inc.Gemtesa$32$12,27122 claims
NovartisEntresto$325$9,39616 claims
AbbVieSynthroid$544$6,71279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →